New Agent to Manage Cancer Related Effusions
Melbourne, Australia - 3 February 2010- In the USA each year, 200,000 cancer patients suffer from a malignant pleural effusion - development of excessive fluid (pleural effusion) in the chest. Several litres of such fluid can accumulate, and m
Online, February 3, 2010 (Newswire.com) - One in four patients with lung cancer, one in every three with breast cancer and most of the patients with mesothelioma will develop a malignant effusion. The current strategy is to induce a pleurodesis (seal the pleural cavity with a chemical agent so no fluid can accumulate). However existing agents are far from perfect, with most producing significant side effects while delivering low success rates.
A recent issue of Respirology published by Wiley-Blackwell features two papers that propose the use of a new alternative pleurodesing agent, Iodoprovidone. They evaluate iodopovidone as a pleurodesis agent and found that it demonstrated good efficiency and safety, making it a good option in the management of malignant pleural effusion.
"There is not only a need to identify ideal pleurodesis agents, but also to standardize and optimize research tools to evaluate pleurodesis success in malignant effusions. In combination, these papers are complementary and warrant a critical appraisal of the current state of clinical research in malignant pleural effusion", said Andreas H. Diacon in an editorial published in the same issue of Respirology.
Pleurodesis is widely used to manage pleural diseases, such as malignant pleural effusion, by promoting pleural obliteration and preventing accumulation of air or fluid in the pleural space. This process would ideally alleviate shortness of breath, cough and pain associated with the presence of tumor and fluid in the pleural space.
In the paper, "Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits", researchers used a rabbit model to compare the effectiveness of iodopovidone in causing pleurodesis with that of doxycycline.
The study found that iodopovidone can induce pleurodesis as efficaciously as doxycycline and demonstrated that the desired outcome of pleurodesis can be achieved without prohibitive toxicity with a range of doses applicable to humans.
The other paper "Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions" is a retrospective analysis of iodopovidone pleurodesis in patients with malignant pleural effusions treated in a tertiary cancer institution.
Lead author Jose D.A. Neto said, "Out of the 61 pleurodesis procedures performed, no mortality was observed and less than 20 per cent presented complications. With the success rate of about 99 percent, iodopovidone appears to be a good option for the recurrent malignant pleural effusion."
***
These articles are published in the January issue of Respirology (Vol. 15, Issue 1). Media wishing to receive a PDF should contact Alina Boey, Senior Manager, Corporate Communications at aboey@wiley.com or phone 65-96565580.
This press release is also available online the Wiley Press Room.
The abstract of "Iodopovidone is as effective as doxycycline in producing pleurosis in rabbits" is available online at: http://www3.interscience.wiley.com/journal/123226685/abstract
The abstract of "Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions" is available online at: http://www3.interscience.wiley.com/journal/123189226/abstract
About Respirology
Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and experimental respiratory biology and disease and its related fields of research including thoracic surgery, internal medicine, immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology and physiology.
About Wiley
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for 200 years, helping people around the world meet their needs and fulfill their aspirations. Since 1901, Wiley and its acquired companies have published the works of more than 400 Nobel laureates in all categories: Literature, Economics, Physiology/Medicine, Chemistry and Peace.
Our core businesses include scientific, technical, medical and scholarly journals, encyclopedias, books, and online products and services; professional/trade publishes books, subscription products, training materials, and online applications and websites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
About Wiley-Blackwell
Wiley-Blackwell is the international scientific, technical, medical and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or www.interscience.wiley.com.
***ENDS***